Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?

Shelby Davies; Gabrielle Gold-Von Simson

doi:10.1007/s00246-013-0731-3

Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?

Shelby Davies, Gabrielle Gold-Von Simson

Pediatrics

Research output: Contribution to journal › Letter

7 Scopus citations

Original language	English (US)
Number of pages	1
Journal	Pediatric Cardiology
Volume	34
Issue number	7
DOIs	https://doi.org/10.1007/s00246-013-0731-3
State	Published - Oct 1 2013

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s00246-013-0731-3

Cite this

Davies, S., & Gold-Von Simson, G. (2013). Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy? Pediatric Cardiology, 34(7). https://doi.org/10.1007/s00246-013-0731-3

@article{385517ce99ab4bd39d6cf17799c0c25f,

title = "Should infliximab be used as an adjuvant to IVIG in the treatment of children with kawasaki disease who are at high risk for resistance to conventional therapy?",

author = "Shelby Davies and {Gold-Von Simson}, Gabrielle",

year = "2013",

month = oct,

day = "1",

doi = "10.1007/s00246-013-0731-3",

language = "English (US)",

volume = "34",

journal = "Pediatric Cardiology",

issn = "0172-0643",